metformin has been researched along with Vascular Calcification in 10 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Vascular Calcification: Deposition of calcium into the blood vessel structures. Excessive calcification of the vessels are associated with ATHEROSCLEROTIC PLAQUES formation particularly after MYOCARDIAL INFARCTION (see MONCKEBERG MEDIAL CALCIFIC SCLEROSIS) and chronic kidney diseases which in turn increase VASCULAR STIFFNESS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Vascular calcification (VC) is inhibited by the glycoprotein osteoprotegerin (OPG)." | 7.81 | The effects of insulin and liraglutide on osteoprotegerin and vascular calcification in vitro and in patients with type 2 diabetes. ( Agha, A; Ashley, DT; Cummins, PM; Davenport, C; Forde, H; Mahmood, WA; McAdam, B; McDermott, J; McGrath, F; Smith, D; Sreenan, S; Thompson, CJ, 2015) |
| "Vascular calcification is associated with aging, type 2 diabetes, and atherosclerosis, and increases the risk of cardiovascular morbidity and mortality." | 5.72 | Metformin protects against vascular calcification through the selective degradation of Runx2 by the p62 autophagy receptor. ( Caporali, A; Corcoran, BM; Forsythe, RO; Jones, RA; Koo, E; MacRae, VE; Phadwal, K; Tang, K; Tang, Q, 2022) |
| " Methods and Results The Diabetes Prevention Program was a randomized controlled trial comparing an intensive lifestyle intervention, metformin, or placebo for prevention of type 2 diabetes among patients with prediabetes." | 5.69 | Coronary Artery Calcium and Cognitive Decline in the Diabetes Prevention Program Outcomes Study. ( Crandall, JP; Dabelea, D; Gadde, KM; Goldberg, RB; Ibebuogu, UN; Luchsinger, JA; Orchard, TJ; Pi-Sunyer, FX; Schlögl, M; Temprosa, M; Watson, KE; Yin, X, 2023) |
| "Metformin (Met) is an antidiabetic drug with beneficial cardiovascular disease effects." | 5.62 | Metformin attenuates hyperlipidaemia-associated vascular calcification through anti-ferroptotic effects. ( Liu, NF; Ma, WQ; Sun, XJ; Zhu, Y, 2021) |
| "Vascular calcification (VC) is inhibited by the glycoprotein osteoprotegerin (OPG)." | 3.81 | The effects of insulin and liraglutide on osteoprotegerin and vascular calcification in vitro and in patients with type 2 diabetes. ( Agha, A; Ashley, DT; Cummins, PM; Davenport, C; Forde, H; Mahmood, WA; McAdam, B; McDermott, J; McGrath, F; Smith, D; Sreenan, S; Thompson, CJ, 2015) |
| "Vascular calcification is associated with aging, type 2 diabetes, and atherosclerosis, and increases the risk of cardiovascular morbidity and mortality." | 1.72 | Metformin protects against vascular calcification through the selective degradation of Runx2 by the p62 autophagy receptor. ( Caporali, A; Corcoran, BM; Forsythe, RO; Jones, RA; Koo, E; MacRae, VE; Phadwal, K; Tang, K; Tang, Q, 2022) |
| "Metformin (Met) is an antidiabetic drug with beneficial cardiovascular disease effects." | 1.62 | Metformin attenuates hyperlipidaemia-associated vascular calcification through anti-ferroptotic effects. ( Liu, NF; Ma, WQ; Sun, XJ; Zhu, Y, 2021) |
| "Metformin-treated rats did not develop hyperphosphatemia or hypocalcemia and this prevented the development of vascular calcification and inhibited the progression toward high bone turnover disease." | 1.48 | Metformin prevents the development of severe chronic kidney disease and its associated mineral and bone disorder. ( Brand, K; D'Haese, PC; De Broe, ME; De Maré, A; Gottwald-Hostalek, U; Kamel, S; Lalau, JD; Neven, E; Opdebeeck, B; Verhulst, A; Vervaet, B, 2018) |
| "Metformin-treated patients had a significantly lower calcification score than metformin-free patients (mean ± standard deviation: 2033 ± 4514 and 4684 ± 9291, respectively; p = 0." | 1.46 | Association between metformin use and below-the-knee arterial calcification score in type 2 diabetic patients. ( Aubert, CE; Bourron, O; Cluzel, P; Hartemann, A; Kamel, S; Kemel, S; Lalau, JD; Lenglet, A; Liabeuf, S; Mary, A; Massy, ZA; Mentaverri, R; Salem, JE, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 4 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Phadwal, K | 1 |
| Koo, E | 1 |
| Jones, RA | 1 |
| Forsythe, RO | 1 |
| Tang, K | 1 |
| Tang, Q | 1 |
| Corcoran, BM | 1 |
| Caporali, A | 1 |
| MacRae, VE | 1 |
| Gadde, KM | 1 |
| Yin, X | 1 |
| Goldberg, RB | 1 |
| Orchard, TJ | 1 |
| Schlögl, M | 1 |
| Dabelea, D | 1 |
| Ibebuogu, UN | 1 |
| Watson, KE | 1 |
| Pi-Sunyer, FX | 1 |
| Crandall, JP | 1 |
| Temprosa, M | 1 |
| Luchsinger, JA | 1 |
| Lee, J | 1 |
| Hong, SW | 1 |
| Kim, MJ | 1 |
| Kwon, H | 1 |
| Park, SE | 1 |
| Rhee, EJ | 1 |
| Lee, WY | 1 |
| Ma, WQ | 1 |
| Sun, XJ | 1 |
| Zhu, Y | 1 |
| Liu, NF | 1 |
| Neven, E | 2 |
| Vervaet, B | 1 |
| Brand, K | 1 |
| Gottwald-Hostalek, U | 1 |
| Opdebeeck, B | 2 |
| De Maré, A | 2 |
| Verhulst, A | 2 |
| Lalau, JD | 2 |
| Kamel, S | 2 |
| De Broe, ME | 1 |
| D'Haese, PC | 2 |
| Maudsley, S | 1 |
| Azmi, A | 1 |
| De Leger, W | 1 |
| Meijers, B | 1 |
| Evenepoel, P | 1 |
| Cao, X | 1 |
| Li, H | 1 |
| Tao, H | 1 |
| Wu, N | 1 |
| Yu, L | 1 |
| Zhang, D | 1 |
| Lu, X | 1 |
| Zhu, J | 1 |
| Lu, Z | 1 |
| Zhu, Q | 1 |
| Davenport, C | 1 |
| Mahmood, WA | 1 |
| Forde, H | 1 |
| Ashley, DT | 1 |
| Agha, A | 1 |
| McDermott, J | 1 |
| Sreenan, S | 1 |
| Thompson, CJ | 1 |
| McGrath, F | 1 |
| McAdam, B | 1 |
| Cummins, PM | 1 |
| Smith, D | 1 |
| Zhang, X | 1 |
| Xiao, J | 1 |
| Li, R | 1 |
| Qin, X | 1 |
| Wang, F | 1 |
| Mao, Y | 1 |
| Liang, W | 1 |
| Sheng, X | 1 |
| Guo, M | 1 |
| Song, Y | 1 |
| Ji, X | 1 |
| Mary, A | 1 |
| Hartemann, A | 1 |
| Liabeuf, S | 1 |
| Aubert, CE | 1 |
| Kemel, S | 1 |
| Salem, JE | 1 |
| Cluzel, P | 1 |
| Lenglet, A | 1 |
| Massy, ZA | 1 |
| Mentaverri, R | 1 |
| Bourron, O | 1 |
1 trial available for metformin and Vascular Calcification
| Article | Year |
|---|---|
Coronary Artery Calcium and Cognitive Decline in the Diabetes Prevention Program Outcomes Study.
Topics: Adult; Calcinosis; Calcium; Calcium, Dietary; Cognitive Dysfunction; Coronary Artery Disease; Corona | 2023 |
9 other studies available for metformin and Vascular Calcification
| Article | Year |
|---|---|
Metformin protects against vascular calcification through the selective degradation of Runx2 by the p62 autophagy receptor.
Topics: AMP-Activated Protein Kinases; Autophagy; Cells, Cultured; Core Binding Factor Alpha 1 Subunit; Diab | 2022 |
Metformin, resveratrol, and exendin-4 inhibit high phosphate-induced vascular calcification via AMPK-RANKL signaling.
Topics: AMP-Activated Protein Kinases; Animals; Cell Line; Enzyme Activators; Exenatide; Metformin; Muscle, | 2020 |
Metformin attenuates hyperlipidaemia-associated vascular calcification through anti-ferroptotic effects.
Topics: Animals; Humans; Hyperlipidemias; Metformin; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Rats | 2021 |
Metformin prevents the development of severe chronic kidney disease and its associated mineral and bone disorder.
Topics: Adenine; Animals; Chronic Kidney Disease-Mineral and Bone Disorder; Disease Models, Animal; Humans; | 2018 |
Indoxyl Sulfate and p-Cresyl Sulfate Promote Vascular Calcification and Associate with Glucose Intolerance.
Topics: Animals; Biological Products; Biopsy, Needle; Carbamates; Disease Models, Animal; Glucose Intoleranc | 2019 |
Metformin inhibits vascular calcification in female rat aortic smooth muscle cells via the AMPK-eNOS-NO pathway.
Topics: AMP-Activated Protein Kinases; Animals; Aorta; Cell Transdifferentiation; Cells, Cultured; Diabetic | 2013 |
The effects of insulin and liraglutide on osteoprotegerin and vascular calcification in vitro and in patients with type 2 diabetes.
Topics: Aged; Alkaline Phosphatase; Cells, Cultured; Core Binding Factor Alpha 1 Subunit; Coronary Vessels; | 2015 |
Metformin alleviates vascular calcification induced by vitamin D3 plus nicotine in rats via the AMPK pathway.
Topics: AMP-Activated Protein Kinases; Animals; Cholecalciferol; Male; Metformin; Nicotine; Rats; Rats, Wist | 2016 |
Association between metformin use and below-the-knee arterial calcification score in type 2 diabetic patients.
Topics: Aged; Chi-Square Distribution; Computed Tomography Angiography; Cross-Sectional Studies; Diabetes Me | 2017 |